IPCA Laboratories

IPCA Laboratories Cash Flow per Share

The Operating Cash Flow per Share of IPCA Laboratories (IPCALAB.NS) as of Nov 21, 2026 is 45.01 INR. In the previous year, Operating Cash Flow per Share was 52.08 INR — a change of -13.57% (lower).

Cash Flow per Share

45.01INR

YoY

-13.57%

Last updated:

Operating Cash Flow per Share of IPCA Laboratories is 2026 45.01 INR. Operating Cash Flow per Share of IPCA Laboratories was 2025 52.08 INR. It decreases by -13.57% lower compared to the previous year.

The IPCA Laboratories Cash Flow per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Flow per Share
Date
Cash Flow per Share
Jan 1, 2019
19.81 INR
Jan 1, 2020
22.66 INR
Jan 1, 2021
42.95 INR
Jan 1, 2022
33.74 INR
Jan 1, 2023
31.76 INR
Jan 1, 2024
40.25 INR
Jan 1, 2025
52.08 INR
Jan 1, 2026
45.01 INR
The IPCA Laboratories Cash Flow per Share history
YEARCash Flow per ShareYoY
45.01INR-13.57%
52.08INR+29.40%
40.25INR+26.72%
31.76INR-5.86%
33.74INR-21.45%
42.95INR+89.58%
22.66INR+14.34%
19.81INR+46.89%
13.49INR+21.40%
11.11INR-60.22%
27.93INR+51.35%
18.46INR-10.35%
20.59INR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

IPCA Laboratories Stock analysis

What does IPCA Laboratories do? Ipca Laboratories Ltd. generates revenue through the manufacturing and marketing of over 350 pharmaceutical formulations and approximately 80 active pharmaceutical ingredients (APIs), including Atenolol, Chloroquine Phosphate, Chlorthalidone, Furosemide, Hydroxychloroquine sulfate, Losartan, Metoprolol Succinate, Metoprolol Tartrate, Pyrantel Salts, and Propranolol. The company sells its branded products such as Zerodol, Lariago, HCQS, Perinorm, Rapither AB, Tenoric, Lumerax, Etova, Fexova, Malirid, Allsuth, Alwiz, AZR 50mg, Bacilon, Cinkona, Clarbact, Glyree MV, Halotop, Luliz, Ozepam, Pacimol, Pari, Xtor-F, Zabpro, Zilast, Ramcor, Sove, and Venpower in more than 100 countries globally. Its subsidiaries, Ipca Pharmaceuticals, Inc., Ipca Laboratories (U.K.) Ltd, and Tonira Exports Limited, support the distribution and sales of these products across international markets. The company's primary customers are healthcare providers, hospitals, and pharmacies in over 100 countries, purchasing both generic APIs and branded formulations. Manufacturing units in India produce APIs and formulations, with the firm's subsidiaries facilitating global market access. The therapeutic segments covered by its products include cardiovascular, antimalarial, and gastrointestinal treatments, among others, driven by the demand for cost-effective pharmaceutical solutions. IPCA Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about IPCA Laboratories stock

Operating Cash Flow per Share of IPCA Laboratories is 45.01 INR in 2026.

Operating Cash Flow per Share of IPCA Laboratories changed from 52.08 INR to 45.01 INR, representing a -13.57% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow per Share IPCA Laboratories since 2006 – with annual values, charts, and detailed analysis.

Operating cash flow per share measures the operating cash generated per outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — IPCA Laboratories

All Key Metrics — IPCA Laboratories